The Federal Trade Commission finalized a consent order requiring telehealth firm NextMed to stop deceptive GLP‑1 weight‑loss advertising, fake testimonials and unfair billing practices, and to pay $150,000 for consumer refunds. The order includes strict marketing and billing disclosure requirements and is presented as an example of enforcement against misleading health claims.

The Federal Trade Commission approved a final order against telehealth provider NextMed and its principals addressing deceptive marketing and billing tied to GLP‑1 weight‑loss programs. The consent order bars use of fake testimonials, misleading efficacy claims, and unfair billing practices; it requires clearer disclosures about treatment, pricing and refund policies, and imposes regular compliance reporting and monitoring. NextMed must also pay $150,000 earmarked for consumer refunds and restitution, and the company faces restrictions designed to prevent recurrence of the tactics that allegedly extracted payments through manipulated reviews and overstated benefits. The FTC framed the action as part of broader efforts to police deceptive health-related commerce, particularly in fast‑growing areas such as weight‑loss medications and online telehealth where marketing can outpace oversight. The order signals increased scrutiny on telehealth platforms’ advertising accuracy and billing transparency and underscores enforcement agencies’ willingness to pursue consumer redress and corrective measures against firms that leverage misleading claims to drive sales.